X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aventis Pharma with Wockhardt - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs WOCKHARDT LTD. - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

WOCKHARDT LTD. 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA WOCKHARDT LTD. SANOFI INDIA/
WOCKHARDT LTD.
 
P/E (TTM) x 38.9 -23.9 - View Chart
P/BV x 8.4 2.4 346.7% View Chart
Dividend Yield % 1.1 0.0 67,457.1%  

Financials

 SANOFI INDIA   WOCKHARDT LTD.
EQUITY SHARE DATA
    SANOFI INDIA
Dec-16
WOCKHARDT LTD.
Mar-18
SANOFI INDIA/
WOCKHARDT LTD.
5-Yr Chart
Click to enlarge
High Rs4,5601,012 450.6%   
Low Rs4,400532 827.8%   
Sales per share (Unadj.) Rs1,028.5355.9 289.0%  
Earnings per share (Unadj.) Rs129.0-60.3 -213.9%  
Cash flow per share (Unadj.) Rs186.0-46.8 -397.7%  
Dividends per share (Unadj.) Rs68.000.01 680,000.0%  
Dividend yield (eoy) %1.50 117,140.6%  
Book value per share (Unadj.) Rs753.6257.8 292.3%  
Shares outstanding (eoy) m23.03110.63 20.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.42.2 200.9%   
Avg P/E ratio x34.7-12.8 -271.3%  
P/CF ratio (eoy) x24.1-16.5 -146.0%  
Price / Book Value ratio x5.93.0 198.6%  
Dividend payout %52.70 -317,834.9%   
Avg Mkt Cap Rs m103,17485,379 120.8%   
No. of employees `0003.66.3 57.9%   
Total wages/salary Rs m3,5929,371 38.3%   
Avg. sales/employee Rs Th6,537.76,295.0 103.9%   
Avg. wages/employee Rs Th991.41,498.3 66.2%   
Avg. net profit/employee Rs Th819.8-1,066.3 -76.9%   
INCOME DATA
Net Sales Rs m23,68639,369 60.2%  
Other income Rs m7081,202 58.9%   
Total revenues Rs m24,39440,571 60.1%   
Gross profit Rs m5,28118 28,857.9%  
Depreciation Rs m1,3131,495 87.8%   
Interest Rs m152,555 0.6%   
Profit before tax Rs m4,661-2,830 -164.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-3,582 0.0%   
Tax Rs m1,691257 658.0%   
Profit after tax Rs m2,970-6,669 -44.5%  
Gross profit margin %22.30 47,965.4%  
Effective tax rate %36.3-9.1 -399.4%   
Net profit margin %12.5-16.9 -74.0%  
BALANCE SHEET DATA
Current assets Rs m15,67333,796 46.4%   
Current liabilities Rs m6,67826,917 24.8%   
Net working cap to sales %38.017.5 217.3%  
Current ratio x2.31.3 186.9%  
Inventory Days Days7679 95.8%  
Debtors Days Days2289 25.0%  
Net fixed assets Rs m8,09839,664 20.4%   
Share capital Rs m230553 41.6%   
"Free" reserves Rs m17,08827,968 61.1%   
Net worth Rs m17,35628,522 60.9%   
Long term debt Rs m021,731 0.0%   
Total assets Rs m25,40081,620 31.1%  
Interest coverage x311.7-0.1 -289,933.6%   
Debt to equity ratio x00.8 0.0%  
Sales to assets ratio x0.90.5 193.3%   
Return on assets %11.8-5.0 -233.2%  
Return on equity %17.1-23.4 -73.2%  
Return on capital %26.9-7.7 -351.1%  
Exports to sales %24.50-   
Imports to sales %28.00-   
Exports (fob) Rs m5,801NA-   
Imports (cif) Rs m6,627NA-   
Fx inflow Rs m7,1459,807 72.9%   
Fx outflow Rs m6,8461,789 382.8%   
Net fx Rs m2998,019 3.7%   
CASH FLOW
From Operations Rs m3,226684 471.4%  
From Investments Rs m-1,5556,302 -24.7%  
From Financial Activity Rs m-1,818-7,695 23.6%  
Net Cashflow Rs m-147-664 22.1%  

Share Holding

Indian Promoters % 0.0 74.5 -  
Foreign collaborators % 60.4 0.0 -  
Indian inst/Mut Fund % 14.4 2.3 626.1%  
FIIs % 14.6 7.7 189.6%  
ADR/GDR % 0.0 0.1 -  
Free float % 10.5 15.4 68.2%  
Shareholders   15,184 67,757 22.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   STERLING BIOTECH  PFIZER  ALEMBIC PHARMA  ORCHID PHARMA LTD  NOVARTIS  

Compare SANOFI INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Lower, Realty and FMCG Stocks Witness Selling(Closing)

After opening the day on a positive note, share markets in India witnessed volatile trading activity and ended in red.

Related Views on News

WOCKHARDT LTD. Announces Quarterly Results (1QFY19); Net Profit Down 81.4% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, WOCKHARDT LTD. has posted a net profit of Rs 862 m (down 81.4% YoY). Sales on the other hand came in at Rs 10 bn (up 13.1% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY19); Net Profit Up 35.1% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, SANOFI INDIA has posted a net profit of Rs 996 m (up 35.1% YoY). Sales on the other hand came in at Rs 7 bn (up 13.8% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Hurricanes Threaten Oil Spike, but the Saudis are Selling...(Vivek Kaul's Diary)

Sep 6, 2018

Oil prices are rising and could go even more higher amid rising tensions in Middle East.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Sep 19, 2018 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA 5-YR ANALYSIS

COMPARE SANOFI INDIA WITH

MARKET STATS